Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study
Current Oncology · 24.09.2025 · 32 (10) · 534
DOI: 10.3390/curroncol32100534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 24.09.2025. Verfasst von Ali Erhan Eren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Non-Muscle Invasive Bladder Neoplasms, Inflammation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Urothelial carcinoma of the bladder (UCB) demonstrates considerable heterogeneity, with markedly varying outcomes between non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The pan-immune-inflammation value (PIV), derived from routine hematological parameters, has emerged as a novel biomarker reflecting systemic inflammation and immune dysregulation. This pilot, exploratory analysis evaluated the prognostic relevance of the PIV in UCB and contextualized PIV against other inflammation-based indices.
Methods
We retrospectively analyzed 119 patients with histologically confirmed UCB who were treated between 2019 and 2024. PIV was calculated as (neutrophils × platelets × monocytes) ÷ lymphocytes. Additional indices included the NLR, SII, SIRI, and PLR. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–Meier analysis, and prognostic factors were assessed using Cox regression.
Results
Among 119 patients (median age, 72 years; 88% male), 68 were diagnosed with NMIBC and 51 with MIBC. Elevated PIV levels were significantly associated with NMIBC progression to MIBC (p = 0.028) and strongly correlated with NLR, SII, SIRI, and PLR. Patients with high PIV exhibited shorter OS (24 vs. 45 months) and PFS (20 vs. 35 months) than those with low patients (p < 0.001). Although the prognostic value was evident in the univariate analyses, PIV did not retain significance in multivariate models.
Conclusion
Elevated PIV levels predict adverse survival outcomes and progression in UCB, underscoring its potential as a cost-effective and accessible biomarker for risk stratification. Prospective validation in larger cohorts is warranted to confirm its role in personalized patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.
- Department of Clinical Oncology, University of Health Sciences Antalya Education and Research Hospital, Antalya 07100, Turkey.
ORCID-Profile: Asim Armagan Aydin, Eren Erdi Aksaray, Arda Durak, Ahmet Unlu, Mahmut Ekrem Islamoglu
Zitieren
APA
Eren, A. E., Aydin, A. A., Aksaray, E. E., Durak, A., Unlu, A., Islamoglu, M. E., Ozturk, B., & Yildiz, M. (2025). Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study. Current Oncology, 32(10), 534. https://doi.org/10.3390/curroncol32100534
Vancouver
Eren AE, Aydin AA, Aksaray EE, Durak A, Unlu A, Islamoglu ME, et al. Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study. Current Oncology. 2025;32(10):534. doi:10.3390/curroncol32100534
BibTeX
@article{Eren2025,
author = {Eren, Ali Erhan and Aydin, Asim Armagan and Aksaray, Eren Erdi and Durak, Arda and Unlu, Ahmet and Islamoglu, Mahmut Ekrem and Ozturk, Banu and Yildiz, Mustafa},
title = {Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {10},
pages = {534},
doi = {10.3390/curroncol32100534}
}
EUVIMED